【藥品庫存】 藥品安全警訊 (藥品回收)：因安定性試驗不純物含量達規格上限，於2023/1/31 公告回收，院內採購之藥品批號【BBF501、BBF521、BBF551】 即日起回收，院內尚有其他非回收批號可使用。更新日期：2023/2/1。 【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人。

Major Depressive Disorder, Generalized Anxiety Disorder.

Escitalopram, the S-enantiomer of citalopram, is a selective serotonin-reuptake inhibitor (SSRI) and an antidepressant.

Concurrent or recent (i.e., within 2 weeks) therapy with a monoamine oxidase (MAO) inhibitor. Concomitant use with pimozide. Known hypersensitivity to escitalopram, citalopram, or any ingredient in the formulation.

C. Escitalopram crosses the placenta and is distributed into the amniotic fluid.

Escitalopram is distributed into human milk.
Because of the potential for serious adverse effects (e.g., excessive somnolence, decreased feeding, weight loss) in nursing infants, caution should be exercised and nursing infants should be observed for adverse reactions when escitalopram is administered to a nursing woman.

Insomnia, nausea, increased sweating, sexual dysfunction (ejaculation disorder [primarily ejaculatory delay], decreased libido, anorgasmia), fatigue, and somnolence.

Acute management of major depressive disorder or generalized anxiety disorder: Initial 10 mg QD; may be increased to 20 mg daily after a minimum of 1 week.

Children <12 years: Limited data available.
Children and Adolescents >12 years: Initial 10 mg QD; may be increased to 20 mg/day after at least 3 weeks.

Dosage adjustment in patients with mild to moderate renal impairment is not necessary, but the drug should be used with caution in those with severe renal impairment.

The recommended dosage of escitalopram in most geriatric patients and those with hepatic impairment is 10 mg once daily.